US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,379.06

+4.600.33%

Number of Gainers:9

Number of Losers:9

Number of Flat:1

PE:- -

High:1,392.07

Open:1,378.91

Low:1,377.90

Close:1,374.47

Loading ...

Pfizer’s xtandi plus leuprolide improves survival in prostate cancer

BRIEF-Xtandi® Plus Leuprolide Significantly Improves Survival Outcomes In Men With Non-Metastatic Hormone-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence

Pfizer Announces Positive Results from Phase 3 EMBARK Study on XTANDI® for Non-Metastatic Hormone-Sensitive Prostate Cancer

Xtandi® Plus Leuprolide Significantly Improves Survival Outcomes in Men With Non-Metastatic Hormone-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence

THOMSON REUTERS

Pfizer Inc - Xtandi Plus Leuprolide Improves Overall Survival

THOMSON REUTERS

Pfizer: No New Safety Signals Were Observed in Analysis, and Safety Results Were Consistent With Demonstrated Safety Profile of Xtandi

THOMSON REUTERS

Pfizer: Embark Met Key Secondary Endpoint

THOMSON REUTERS

EU's von der Leyen survives parliament confidence vote

Warburg Research Sticks to Its Hold Rating for Deutsche Boerse (0H3T)

Moderately bullish activity in Moderna with shares up 0.89%

Fears grow that Texas floods death toll could surge

AstraZeneca price target raised to $97 from $93 at Berenberg

Pfizer’s Inclacumab Study: A Promising Step for Sickle Cell Disease Treatment

Pfizer’s ATGAM Study: A Key Update for Investors

BioNTech’s Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment

Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: A Promising Update

Fortinet Report: OT Cybersecurity Risk Elevates within Executive Leadership Ranks

Gilead Sciences Inc. Advances HIV Prevention Efforts with European Medicines Agency Validation of Lenacapavir Application

BRIEF-Gilead Finalizes Agreement With Global Fund To Accelerate Access To Lenacapavir

Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for Hiv Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1379.0648,"timestamp":1752868799999,"preClose":1374.4666,"halted":0,"volume":95962727,"delay":0,"changeRate":0.003345,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":4.598267,"latestTime":"07-18 16:00:00 EDT","open":1378.9058,"high":1392.0709,"low":1377.9001,"amount":6205677126.969449,"amplitude":0.01031,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.73069,"peRate":21.631713,"turnoverRate":0.006269,"increases":9,"decrements":9,"flats":1,"marketCap":1137445199268.5,"floatMarketCap":1116746960372.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1392.0709,"amplitude":0.01031,"preClose":1374.4666,"low":1377.9001,"pbRate":"3.73069","latestPrice":1379.0648,"volume":95962727,"delay":0,"open":1378.9058,"prevYearClose":1274.8187,"prevWeekClose":1397.679,"prevMonthClose":1377.5769,"prevQuarterClose":1377.5769,"fiveDayClose":1397.679,"twentyDayClose":1359.4229,"sixtyDayClose":1350.4775,"secType":"PLATE","market":"US","turnoverRate":0.006269,"peRate":21.631713,"marketCap":1137445199268.5,"floatMarketCap":1116746960372.5,"timestamp":1752868799999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":9,"down":9,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550164412","title":"Pfizer’s xtandi plus leuprolide improves survival in prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2550164412","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550164412?lang=en_us&edition=fundamental","pubTime":"2025-07-10 19:00","pubTimestamp":1752145250,"startTime":"0","endTime":"0","summary":"Pfizer (PFE) and Astellas Pharma (ALPMY) announced positive topline results from the overall survival, or OS, analysis from the Phase 3 EMBARK stud...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pfizers-xtandi-plus-leuprolide-improves-survival-in-prostate-cancer-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pfizers-xtandi-plus-leuprolide-improves-survival-in-prostate-cancer-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999011175.SGD","BK4007","LU0225284248.USD","LU1057294990.SGD","LU0122379950.USD","BK4581","LU0225771236.USD","BK4533","SG9999001176.USD","SG9999002232.USD","IE00B19Z3581.USD","LU0321505868.SGD","LU1894683264.USD","LU0234572021.USD","LU0321505439.SGD","BK4599","ALPMY","IE00BLSP4452.SGD","LU1894683348.USD","BK4588","SG9999002224.SGD","SGXZ57979304.SGD","IE000M9KFDE8.USD","LU1066051498.USD","PFE","BK4534","IE00BLSP4239.USD","LU0868494617.USD","LU1023059063.AUD","LU0058720904.USD","LU0289739699.SGD","BK4550","LU1066053197.SGD","SG9999001176.SGD","SG9999013999.USD","BK4568","LU1883839398.USD","BK4592","SG9999003800.SGD","IE0002270589.USD","LU0456855351.SGD","LU0985481810.HKD","LU0170899867.USD","LU0306807586.USD","LU0306806265.USD","BK4585","IE00BBT3K403.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2550641766","title":"BRIEF-Xtandi® Plus Leuprolide Significantly Improves Survival Outcomes In Men With Non-Metastatic Hormone-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence","url":"https://stock-news.laohu8.com/highlight/detail?id=2550641766","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550641766?lang=en_us&edition=fundamental","pubTime":"2025-07-10 18:52","pubTimestamp":1752144753,"startTime":"0","endTime":"0","summary":"BRIEF-Xtandi Plus Leuprolide Significantly Improves Survival Outcomes In Men With Non-Metastatic Hormone-Sensitive Prostate Cancer With High-Risk Biochemical RecurrenceJuly 10 (Reuters) - Pfizer Inc P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nFWN3T60R8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","BK4599","BK4007","LU0868494617.USD","LU0225284248.USD","SG9999001176.SGD","BK4581","LU1023059063.AUD","LU0289739699.SGD","BK4588","IE00B19Z3B42.SGD","LU0225771236.USD","SGXZ57979304.SGD","LU1066051498.USD","BK4592","SG9999003800.SGD","SG9999001176.USD","LU0058720904.USD","BK4534","BK4533","LU0306806265.USD","BK4568","BK4550","LU1066053197.SGD","LU0234572021.USD","LU1894683348.USD","LU0321505868.SGD","IE000M9KFDE8.USD","LU0321505439.SGD","LU1883839398.USD","BK4585","LU0170899867.USD","LU0456855351.SGD","LU1894683264.USD","SG9999011175.SGD","IE00BBT3K403.USD","IE00BLSP4239.USD","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU1057294990.SGD","SG9999013999.USD","LU0122379950.USD","PFE","LU0985481810.HKD","IE0002270589.USD","LU0306807586.USD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2550564198","title":"Pfizer Announces Positive Results from Phase 3 EMBARK Study on XTANDI® for Non-Metastatic Hormone-Sensitive Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2550564198","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550564198?lang=en_us&edition=fundamental","pubTime":"2025-07-10 18:45","pubTimestamp":1752144319,"startTime":"0","endTime":"0","summary":"Pfizer Inc. has announced positive topline results from the Phase 3 EMBARK study evaluating the drug XTANDI , in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer  with high-risk biochemical recurrence . The study demonstrated a statistically significant and clinically meaningful improvement in overall survival  for patients treated with XTANDI plus leuprolide compared to placebo plus leuprolide. A favorable trend towards improved OS was also observed for XTANDI monotherapy, although this did not reach statistical significance. Safety results were consistent with the known safety profile of XTANDI, and no new safety signals were detected. These findings suggest a potential benefit in extending life for men with nmHSPC and high-risk BCR following initial curative-intent therapy. The results from this study have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nNDL4kDNh2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU0456855351.SGD","BK4550","IE00BBT3K403.USD","SG9999003800.SGD","IE00BLSP4452.SGD","LU0225771236.USD","LU1023059063.AUD","BK4533","LU0321505439.SGD","BK4534","LU1883839398.USD","IE00BLSP4239.USD","LU0306807586.USD","SG9999011175.SGD","LU0289739699.SGD","LU0058720904.USD","BK4581","IE0002270589.USD","LU1066053197.SGD","PFE","LU1894683348.USD","SG9999002224.SGD","BK4592","BK4007","LU0234572021.USD","LU0321505868.SGD","SG9999013999.USD","IE00B19Z3B42.SGD","SG9999002232.USD","SG9999001176.SGD","BK4599","LU1057294990.SGD","LU0306806265.USD","BK4585","LU0122379950.USD","LU0225284248.USD","LU0868494617.USD","IE000M9KFDE8.USD","LU1894683264.USD","BK4568","SGXZ57979304.SGD","IE00B19Z3581.USD","SG9999001176.USD","BK4588","LU0985481810.HKD","LU0170899867.USD"],"gpt_icon":1},{"id":"2550641936","title":"Xtandi® Plus Leuprolide Significantly Improves Survival Outcomes in Men With Non-Metastatic Hormone-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence","url":"https://stock-news.laohu8.com/highlight/detail?id=2550641936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550641936?lang=en_us&edition=fundamental","pubTime":"2025-07-10 18:45","pubTimestamp":1752144304,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nFWN3T60R8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1894683264.USD","IE00B19Z3581.USD","BK4550","LU0122379950.USD","LU1883839398.USD","IE00B19Z3B42.SGD","LU1894683348.USD","LU0985481810.HKD","SG9999002232.USD","LU1023059063.AUD","BK4007","LU0225284248.USD","IE000M9KFDE8.USD","BK4568","LU0456855351.SGD","LU0234572021.USD","BK4533","SG9999003800.SGD","IE00BLSP4452.SGD","SG9999011175.SGD","LU0868494617.USD","LU0225771236.USD","SG9999013999.USD","BK4592","BK4534","LU0058720904.USD","LU0289739699.SGD","LU0306807586.USD","BK4585","LU0306806265.USD","LU0170899867.USD","LU0321505868.SGD","SG9999001176.USD","LU0321505439.SGD","LU1066051498.USD","LU1066053197.SGD","IE00BLSP4239.USD","LU1057294990.SGD","SG9999001176.SGD","SGXZ57979304.SGD","SG9999002224.SGD","IE0002270589.USD","IE00BBT3K403.USD","BK4581","PFE","BK4588","BK4599"],"gpt_icon":0},{"id":"2550641935","title":"Pfizer Inc - Xtandi Plus Leuprolide Improves Overall Survival","url":"https://stock-news.laohu8.com/highlight/detail?id=2550641935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550641935?lang=en_us&edition=fundamental","pubTime":"2025-07-10 18:45","pubTimestamp":1752144304,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nFWN3T60R8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1066051498.USD","LU1883839398.USD","BK4581","LU0289739699.SGD","LU0306807586.USD","BK4550","LU0321505439.SGD","LU0868494617.USD","BK4599","SG9999011175.SGD","LU0122379950.USD","LU0225771236.USD","SG9999001176.USD","LU0058720904.USD","BK4007","SG9999003800.SGD","LU0456855351.SGD","LU0306806265.USD","PFE","IE00BLSP4452.SGD","LU0170899867.USD","LU0321505868.SGD","SG9999002224.SGD","BK4533","IE000M9KFDE8.USD","LU1023059063.AUD","SG9999001176.SGD","BK4568","LU1066053197.SGD","BK4534","IE00BLSP4239.USD","SG9999013999.USD","BK4585","LU1894683348.USD","LU0985481810.HKD","SGXZ57979304.SGD","BK4588","BK4592","IE00BBT3K403.USD","IE00B19Z3581.USD","LU0225284248.USD","IE00B19Z3B42.SGD","LU1894683264.USD","LU1057294990.SGD","IE0002270589.USD","SG9999002232.USD","LU0234572021.USD"],"gpt_icon":0},{"id":"2550419816","title":"Pfizer: No New Safety Signals Were Observed in Analysis, and Safety Results Were Consistent With Demonstrated Safety Profile of Xtandi","url":"https://stock-news.laohu8.com/highlight/detail?id=2550419816","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550419816?lang=en_us&edition=fundamental","pubTime":"2025-07-10 18:45","pubTimestamp":1752144304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nFWN3T60R8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0321505868.SGD","LU1894683264.USD","PFE","LU1883839398.USD","LU1023059063.AUD","BK4534","BK4585","LU0321505439.SGD","LU1057294990.SGD","IE00B19Z3581.USD","SGXZ57979304.SGD","BK4568","LU0170899867.USD","BK4592","SG9999001176.USD","LU0868494617.USD","IE00BBT3K403.USD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU0289739699.SGD","LU1066053197.SGD","LU0234572021.USD","SG9999002232.USD","BK4599","BK4007","LU0985481810.HKD","LU0058720904.USD","BK4581","IE0002270589.USD","LU0306807586.USD","SG9999001176.SGD","SG9999011175.SGD","BK4550","BK4533","IE00BLSP4239.USD","SG9999002224.SGD","SG9999003800.SGD","BK4588","LU0122379950.USD","LU1066051498.USD","LU0225771236.USD","LU1894683348.USD","SG9999013999.USD","IE00BLSP4452.SGD","LU0456855351.SGD","LU0306806265.USD","LU0225284248.USD"],"gpt_icon":0},{"id":"2550364193","title":"Pfizer: Embark Met Key Secondary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2550364193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550364193?lang=en_us&edition=fundamental","pubTime":"2025-07-10 18:45","pubTimestamp":1752144304,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nFWN3T60R8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0985481810.HKD","BK4533","LU1057294990.SGD","SG9999003800.SGD","LU0289739699.SGD","LU0306806265.USD","BK4534","BK4585","IE00BLSP4239.USD","BK4581","LU1023059063.AUD","PFE","BK4588","BK4550","SG9999001176.USD","LU1066051498.USD","IE00BBT3K403.USD","BK4007","IE0002270589.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0234572021.USD","LU0122379950.USD","BK4592","IE00BLSP4452.SGD","SG9999002224.SGD","BK4599","IE000M9KFDE8.USD","SGXZ57979304.SGD","SG9999002232.USD","LU0868494617.USD","LU0306807586.USD","LU0225284248.USD","LU1066053197.SGD","SG9999001176.SGD","LU0170899867.USD","SG9999011175.SGD","LU0321505868.SGD","LU1894683264.USD","LU1894683348.USD","SG9999013999.USD","LU0456855351.SGD","LU1883839398.USD","LU0058720904.USD","BK4568","LU0225771236.USD","LU0321505439.SGD"],"gpt_icon":0},{"id":"2550645710","title":"EU's von der Leyen survives parliament confidence vote","url":"https://stock-news.laohu8.com/highlight/detail?id=2550645710","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550645710?lang=en_us&edition=fundamental","pubTime":"2025-07-10 18:03","pubTimestamp":1752141828,"startTime":"0","endTime":"0","summary":"EU's von der Leyen survives parliament confidence vote BRUSSELS, July 10 (Reuters) - European Commission President Ursula von der Leyen survived a no-confidence vote in European Parliament on Thursday","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nS8N3PA03S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU1894683348.USD","IE00BLSP4239.USD","IE0002270589.USD","SG9999001176.USD","BK4550","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU1066053197.SGD","LU0058720904.USD","LU0321505439.SGD","LU0225284248.USD","LU0225771236.USD","SG9999003800.SGD","LU1057294990.SGD","BK4534","LU1066051498.USD","IE00B19Z3581.USD","LU0868494617.USD","LU1894683264.USD","BK4533","IE00BLSP4452.SGD","BK4599","BK4568","BK4585","LU0321505868.SGD","BK4581","SG9999001176.SGD","SGXZ57979304.SGD","LU0306806265.USD","LU0170899867.USD","SG9999002232.USD","SG9999011175.SGD","BK4592","LU0234572021.USD","LU0456855351.SGD","LU0985481810.HKD","SG9999013999.USD","LU1023059063.AUD","IE00BBT3K403.USD","BK4007","BK4588","LU0289739699.SGD","LU0122379950.USD","LU1883839398.USD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2550005645","title":"Warburg Research Sticks to Its Hold Rating for Deutsche Boerse (0H3T)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550005645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550005645?lang=en_us&edition=fundamental","pubTime":"2025-07-10 17:55","pubTimestamp":1752141318,"startTime":"0","endTime":"0","summary":"Warburg Research analyst Andreas Plaesier maintained a Hold rating on Deutsche Boerse today and set a price target of €281.00. The company’s shares...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/warburg-research-sticks-to-its-hold-rating-for-deutsche-boerse-0h3t-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/warburg-research-sticks-to-its-hold-rating-for-deutsche-boerse-0h3t-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4139","BK4588","BK4548","BK4551","BK4568","BK4585","BNTX"],"gpt_icon":0},{"id":"2550566365","title":"Moderately bullish activity in Moderna with shares up 0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550566365","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550566365?lang=en_us&edition=fundamental","pubTime":"2025-07-10 04:20","pubTimestamp":1752092415,"startTime":"0","endTime":"0","summary":"Moderately bullish activity in Moderna (MRNA), with shares up 29c, or 0.89%, near $32.83. Options volume more than double the daily average with 20...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-moderna-with-shares-up-0-89-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-moderna-with-shares-up-0-89-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","BK4139","BK4501","BK4532","BK4588","MRNA","BK4548","BK4551","BK4568","BK4534","BK4585"],"gpt_icon":0},{"id":"2550666189","title":"Fears grow that Texas floods death toll could surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2550666189","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550666189?lang=en_us&edition=fundamental","pubTime":"2025-07-10 03:42","pubTimestamp":1752090120,"startTime":"0","endTime":"0","summary":"HUNT, Texas:Fears grew Wednesday  that the death toll of 110 in the Texas floods could still surge as hopes fade of finding survivors among the many reported still missing several days after the disaster.More than 170 people remain unaccounted for after the flash flooding on the Fourth of July holiday, a tragedy that shocked many Americans.After torrents of river water roared through several Texas counties - some striking in the middle of the night - rescuers still worked to find bodies and any survivors as state Governor Greg Abbott warned that the final toll was not yet known.Officials in Kerr County, the epicentre of the flooding, on Wednesday confirmed 161 people were known to be missing in the county. Twelve others remain unaccounted for elsewhere in the state.A small boat and tree limbs are left behind after flooding in Kerrville, Texas on Wednesday, July 9, 2025. . People search along the Guadalupe River after flooding in Kerrville, Texas on Wednesday , July 9, 2025. . In the ne","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--qsKsIAAi--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_one-cms:core:watermark:ap_data-1,w_0.1/f_auto,q_auto/v1/one-cms/core/aptopix_texas_floods_extreme_weather_90712.jpg?itok=s-qCBVCg","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--qsKsIAAi--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_one-cms:core:watermark:ap_data-1,w_0.1/f_auto,q_auto/v1/one-cms/core/aptopix_texas_floods_extreme_weather_90712.jpg?itok=s-qCBVCg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/world/texas-flood-victims-climate-change-trump-governor-abbott-5230051","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["LU0122379950.USD","LU0266013472.USD","SG9999004303.SGD","LU1721429402.USD","LU2112291526.USD","BK4592","LU2468319806.SGD","LU1061106388.HKD","IE00B4R5TH58.HKD","LU1989763690.USD","IE00B2B36J28.USD","BK4585","LU0234572021.USD","LU1721429741.USD","BK4533","LU2089984988.USD","SG9999002224.SGD","ABT","LU2133065610.SGD","SGXZ23171101.USD","LU2237957902.USD","NWS","LU0170899867.USD","LU1023059063.AUD","LU1989763427.SGD","IE0009355771.USD","LU0868494617.USD","LU1914381329.SGD","LU1057294990.SGD","IE00BFTCPJ56.SGD","BK4111","BK4504","BK4082","BK4566","IE00BJJMRZ35.SGD","LU1691799644.USD","SG9999002232.USD","BK4588","IE0002141913.USD","BK4568","BK4581","IE00BJT1NW94.SGD","LU2237957811.SGD"],"gpt_icon":0},{"id":"2550685196","title":"AstraZeneca price target raised to $97 from $93 at Berenberg","url":"https://stock-news.laohu8.com/highlight/detail?id=2550685196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550685196?lang=en_us&edition=fundamental","pubTime":"2025-07-10 03:40","pubTimestamp":1752090023,"startTime":"0","endTime":"0","summary":"Berenberg analyst Luisa Hector raised the firm’s price target on AstraZeneca (AZN) to $97 from $93 and keeps a Buy rating on the shares. The firm i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-price-target-raised-to-97-from-93-at-berenberg-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-price-target-raised-to-97-from-93-at-berenberg-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0320765992.SGD","LU2417539215.USD","LU0889565916.HKD","AZN","BK4007","LU1829250122.USD","LU2236285917.USD","BK4588","BK4568","LU2462157665.USD","LU2456880835.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2550654144","title":"Pfizer’s Inclacumab Study: A Promising Step for Sickle Cell Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2550654144","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550654144?lang=en_us&edition=fundamental","pubTime":"2025-07-10 00:15","pubTimestamp":1752077753,"startTime":"0","endTime":"0","summary":"Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a clinical study titled ‘An Open-label Extension...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pfizers-inclacumab-study-a-promising-step-for-sickle-cell-disease-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pfizers-inclacumab-study-a-promising-step-for-sickle-cell-disease-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1023059063.AUD","BK4599","BK4533","IE000M9KFDE8.USD","SG9999002232.USD","LU0058720904.USD","BK4534","LU1894683348.USD","SG9999003800.SGD","IE00B19Z3B42.SGD","SG9999013999.USD","LU0289739699.SGD","LU0456855351.SGD","IE0002270589.USD","LU0306806265.USD","LU0321505439.SGD","LU0234572021.USD","SG9999002224.SGD","LU0225284248.USD","SG9999001176.USD","SG9999001176.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0170899867.USD","BK4568","LU0985481810.HKD","LU1057294990.SGD","LU0868494617.USD","BK4581","BK4585","BK4592","IE00BLSP4239.USD","LU1066051498.USD","LU1066053197.SGD","LU0225771236.USD","LU1883839398.USD","PFE","LU1894683264.USD","SG9999011175.SGD","BK4007","BK4588","LU0321505868.SGD","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU0306807586.USD","LU0122379950.USD","BK4550"],"gpt_icon":0},{"id":"2550146654","title":"Pfizer’s ATGAM Study: A Key Update for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2550146654","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550146654?lang=en_us&edition=fundamental","pubTime":"2025-07-10 00:13","pubTimestamp":1752077616,"startTime":"0","endTime":"0","summary":"Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Study Overview: Pfizer Inc. is conducting a study titled ‘ATGAM Intravenou...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pfizers-atgam-study-a-key-update-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pfizers-atgam-study-a-key-update-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BBT3K403.USD","BK4592","BK4599","IE00B19Z3B42.SGD","LU0058720904.USD","LU0289739699.SGD","BK4581","IE00BLSP4239.USD","BK4550","LU1883839398.USD","ISBC","IE0002270589.USD","BK4211","BK4534","SG9999011175.SGD","SG9999002224.SGD","BK4533","LU0321505868.SGD","SG9999001176.SGD","SG9999002232.USD","LU0225284248.USD","LU0985481810.HKD","LU0456855351.SGD","LU1057294990.SGD","LU1894683264.USD","BK4568","IE00B19Z3581.USD","LU1066053197.SGD","SG9999001176.USD","BK4588","SG9999013999.USD","IE00BLSP4452.SGD","SGXZ57979304.SGD","LU0321505439.SGD","IE000M9KFDE8.USD","LU0306806265.USD","LU0306807586.USD","LU0234572021.USD","LU1066051498.USD","LU1023059063.AUD","LU0122379950.USD","LU1894683348.USD","BK4007","LU0868494617.USD","LU0225771236.USD","PFE","SG9999003800.SGD","LU0170899867.USD","BK4585"],"gpt_icon":0},{"id":"2550651005","title":"BioNTech’s Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2550651005","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550651005?lang=en_us&edition=fundamental","pubTime":"2025-07-10 00:01","pubTimestamp":1752076894,"startTime":"0","endTime":"0","summary":"Biontech Se Sponsored Adr (($BNTX)), Biontech SE (($CC:BNTX.CUR)) announced an update on their ongoing clinical study. Study Overview: BioNTech SE,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biontechs-phase-iii-trial-a-potential-game-changer-in-endometrial-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biontechs-phase-iii-trial-a-potential-game-changer-in-endometrial-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4134","BK4585","BK4139","BK4551","BK4548","BK4535","BK4568","III","BNTX"],"gpt_icon":0},{"id":"2550832654","title":"Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: A Promising Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2550832654","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550832654?lang=en_us&edition=fundamental","pubTime":"2025-07-10 00:00","pubTimestamp":1752076830,"startTime":"0","endTime":"0","summary":"Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1B study titled ‘A Study to Evaluate the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pfizers-gene-therapy-study-for-duchenne-muscular-dystrophy-a-promising-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pfizers-gene-therapy-study-for-duchenne-muscular-dystrophy-a-promising-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4592","LU0234572021.USD","IE00BLSP4239.USD","LU0306807586.USD","LU1066051498.USD","LU0868494617.USD","BK4581","IE00BLSP4452.SGD","SG9999001176.USD","BK4585","SG9999003800.SGD","BK4007","SG9999011175.SGD","LU0122379950.USD","LU1066053197.SGD","LU0225771236.USD","LU0306806265.USD","BK4568","LU1894683348.USD","IE00BBT3K403.USD","BK4588","SG9999013999.USD","LU1023059063.AUD","LU0058720904.USD","BK4533","LU1057294990.SGD","IE00B19Z3581.USD","SG9999001176.SGD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4550","LU0225284248.USD","LU0321505439.SGD","LU1883839398.USD","LU0321505868.SGD","SG9999002232.USD","LU0985481810.HKD","PFE","LU1894683264.USD","BK4599","LU0456855351.SGD","SGXZ57979304.SGD","LU0289739699.SGD","SG9999002224.SGD","BK4534","LU0170899867.USD"],"gpt_icon":0},{"id":"2550630255","title":"Fortinet Report: OT Cybersecurity Risk Elevates within Executive Leadership Ranks","url":"https://stock-news.laohu8.com/highlight/detail?id=2550630255","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550630255?lang=en_us&edition=fundamental","pubTime":"2025-07-09 21:00","pubTimestamp":1752066000,"startTime":"0","endTime":"0","summary":"More than half (52%) of organizations report that the CISO/CSO is responsible for OT, up from 16% in 2022, while 95% of organizations report that the C-suite is responsible for OT, up from 41% in 2022","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/09/3112603/0/en/Fortinet-Report-OT-Cybersecurity-Risk-Elevates-within-Executive-Leadership-Ranks.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1974910355.USD","LU0348723411.USD","FTNT","BK4560","BK4532","LU0079474960.USD","LU1917777945.USD","LU2023250843.SGD","BK4568","LU2286300806.USD","BK4097","BK4588","BK4086","APT","IE0008368304.USD","LU2023250504.SGD","LU2106854487.HKD","LU0170899867.USD"],"gpt_icon":0},{"id":"2550632694","title":"Gilead Sciences Inc. Advances HIV Prevention Efforts with European Medicines Agency Validation of Lenacapavir Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2550632694","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550632694?lang=en_us&edition=fundamental","pubTime":"2025-07-09 20:00","pubTimestamp":1752062445,"startTime":"0","endTime":"0","summary":"Gilead Sciences Inc. has announced a strategic partnership with the Global Fund to Fight AIDS, Tuberculosis and Malaria to accelerate access to lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for HIV prevention in primarily low- and lower-middle-income countries. This agreement will enable Gilead to supply the medicine to up to two million people over three years at no profit, while awaiting the availability of licensed generic versions. The European Medicines Agency has validated Gilead's application for lenacapavir under the EU-M4all procedure, which could expedite regulatory reviews in resource-limited countries. Gilead is actively collaborating with global aid organizations to ensure timely distribution and is pursuing strategies to support access in middle-income countries not covered by this agreement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL5gT12M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","LU0234570918.USD","LU1430594728.SGD","IE00BKVL7J92.USD","BK4583","LU2468319806.SGD","IE00B3T34201.USD","LU1674673691.USD","LU0109394709.USD","LU1839511570.USD","BK4550","LU1066053197.SGD","BK4585","BK4139","LU1674673428.USD","LU2089984988.USD","LU0058720904.USD","BK4532","GILD","LU0289739699.SGD","IE00BSNM7G36.USD","LU0889565916.HKD","LU1585245621.USD","SG9999015952.SGD","SG9999015986.USD","LU0320765992.SGD","BK4578","IE00B19Z3B42.SGD","LU2087621335.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","LU1571399168.USD","LU2324357040.USD","BK4566","SG9999015945.SGD","BK4588","LU0823416689.USD","SG9999015978.USD","BK4568","IE0002270589.USD","LU1066051498.USD"],"gpt_icon":0},{"id":"2550025655","title":"BRIEF-Gilead Finalizes Agreement With Global Fund To Accelerate Access To Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2550025655","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550025655?lang=en_us&edition=fundamental","pubTime":"2025-07-09 20:00","pubTimestamp":1752062403,"startTime":"0","endTime":"0","summary":"BRIEF-Gilead Finalizes Agreement With Global Fund To Accelerate Access To Lenacapavir July 9  - Gilead Sciences Inc GILD.O:GILEAD SCIENCES: AGREEMENT WITH GLOBAL FUND TO ACCELERATE ACCESS TO LENACAPAVIR FOR HIV PREVENTION IN LOW-INCOME COUNTRIESGILEAD SCIENCES: TO PROVIDE LENACAPAVIR TO 2 MILLION PEOPLE OVER 3 YEARS IN COUNTRIES SUPPORTED BY GLOBAL FUND, AT NO PROFIT TO GILEADFurther company coverage: GILD.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nP8N3JT0KN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","LU0289739699.SGD","LU0109394709.USD","BK4568","BK4588","LU1839511570.USD","LU0058720904.USD","IE0002270589.USD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU2324357040.USD","SG9999015978.USD","LU1430594728.SGD","IE00BKVL7J92.USD","LU1571399168.USD","LU1066051498.USD","SG9999015945.SGD","IE00BSNM7G36.USD","LU0320765992.SGD","LU0234570918.USD","LU1674673691.USD","BK4139","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","BK4550","BK4578","SG9999015986.USD","LU0889565916.HKD","BK4583","LU2089984988.USD","LU2087621335.USD","BK4585","IE00B3T34201.USD","LU1674673428.USD","BK4532","LU1778281490.HKD","LU1585245621.USD","BK4566","GILD","LU0823416689.USD","SG9999015952.SGD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2550632514","title":"Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for Hiv Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2550632514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550632514?lang=en_us&edition=fundamental","pubTime":"2025-07-09 20:00","pubTimestamp":1752062401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nTUA3DXZCC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1066053197.SGD","BK4550","LU2324357040.USD","LU1066051498.USD","SG9999015952.SGD","LU0109394709.USD","LU1778281490.HKD","GILD","LU0289739699.SGD","BK4532","LU2089984988.USD","SG9999015945.SGD","BK4588","IE00B19Z3581.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU1674673691.USD","BK4578","LU0889565916.HKD","LU0058720904.USD","LU1571399168.USD","BK4585","LU0234570918.USD","LU0823416689.USD","LU0320765992.SGD","LU2468319806.SGD","LU1839511570.USD","IE00B19Z3B42.SGD","LU2087621335.USD","LU1585245621.USD","IE00B3T34201.USD","SG9999015978.USD","BK4568","BK4566","LU1430594728.SGD","IE00BKVL7J92.USD","IE0002270589.USD","IE00BSNM7G36.USD","SG9999015986.USD","IE00BZ1G4Q59.USD","BK4583"],"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":9,"totalSize":237,"code":"91000000","status":"200"}]}}